Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nicorandil
Drug ID BADD_D01562
Description Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used for patients with angina who remain symptomatic despite optimal treatment with other antianginal drugs [T28]. Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular concentration of cyclic GMP. It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload [A20325].
Indications and Usage Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.
Marketing Status Not Available
ATC Code C01DX16
DrugBank ID DB09220
KEGG ID D01810
MeSH ID D020108
PubChem ID 47528
TTD Drug ID D0O2SR
NDC Product Code Not Available
Synonyms Nicorandil | 2-Nicotinamidoethyl Nitrate | 2 Nicotinamidoethyl Nitrate | Nitrate, 2-Nicotinamidoethyl | 2-Nicotinamidethyl Nitrate | 2 Nicotinamidethyl Nitrate | Nitrate, 2-Nicotinamidethyl | SG-75 | SG 75 | SG75 | Ikorel | Adancor | Dancor
Chemical Information
Molecular Formula C8H9N3O4
CAS Registry Number 65141-46-0
SMILES C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Sleep disorder19.02.04.001--Not Available
Small intestine ulcer07.04.06.009--
Somnolence19.02.05.003; 17.02.04.006--
Stomatitis07.05.06.005--
Syncope17.02.04.008; 02.01.02.008; 24.06.02.012--
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue ulceration07.14.01.003--Not Available
Ulcer08.03.06.001--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vestibular disorder17.02.02.008; 04.04.02.001--
Vomiting07.01.07.003--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Foetor hepaticus09.01.05.006; 07.01.06.026--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Metabolic disorder14.11.01.001--Not Available
Vasodilation procedure25.03.01.001--Not Available
Connective tissue disorder15.06.01.006--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Blood disorder01.05.01.004--Not Available
Ulcerative keratitis10.02.01.021; 06.04.02.004--
The 3th Page    First    Pre   3    Total 3 Pages